Actively Recruiting
Prostatic Size Reduction Following of Leuprorelin Acetate
Led by Consorci Sanitari de Terrassa · Updated on 2024-09-19
40
Participants Needed
1
Research Sites
45 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine the possible reduction in prostate size following the administration of Leuprelin prior to the application of radiotherapy.
CONDITIONS
Official Title
Prostatic Size Reduction Following of Leuprorelin Acetate
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Man with positive prostate biopsy
- Able to sign informed consent form
- Need for hormonal treatment before starting radiotherapy
You will not qualify if you...
- Prostate size less than 20 cc at diagnosis
- Positive lymph nodes or metastatic prostate cancer on imaging
- Previous pelvic radiation therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital de Terrassa
Terrassa, Barcelona, Spain, 08225
Actively Recruiting
Research Team
N
nicolas feltes
CONTACT
N
nicolas feltes
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here